Story

Carl Zeiss Meditec Revenue Dips on China Weakness, Margin Pressure

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20262 min read
Carl Zeiss Meditec Revenue Dips on China Weakness, Margin Pressure
Text size
Background

Carl Zeiss Meditec reported a decline in revenue and a significant contraction in profit margins for the first nine months of its fiscal year, weighed down by currency headwinds and persistent challenges in the Chinese market. The medical technology company announced on Thursday that it now anticipates a goodwill impairment charge in its Ophthalmology business unit.

Performance Details

For the nine-month period, Carl Zeiss Meditec's revenue fell 2.9% to €1.55 billion, according to the company's disclosure. On a currency-adjusted basis, revenue was flat compared to the prior-year period.

The company's profitability saw a more pronounced decline. The adjusted EBITA margin contracted to 8.0%, down from 11.1% a year earlier. This was attributed to negative currency effects and lower sales of consumables.

China and Ophthalmology Headwinds

The primary driver of the weaker results was the company's ophthalmology segment, which faced several challenges, particularly in China. The company cited a decrease in demand and the withdrawal of a bifocal intraocular lens from a procurement tender, which led to inventory returns and weakened its lens business in the country.

Sample IUX Markets – In-articleAd

Furthermore, the refractive laser business experienced a slowdown due to lower procedure volumes and a more cautious investment environment for new equipment, especially in the Asia-Pacific region. In a contrasting bright spot, the microsurgery unit registered growth, supported by strong deliveries of neurosurgical operating microscopes.

Updated Outlook and Impairment

Looking ahead, Carl Zeiss Meditec provided guidance for the full fiscal year 2025/26, forecasting revenue between €2.15 billion and €2.20 billion. The company expects its adjusted EBITA margin to be in the range of 8% to 10% for the full year.

Reflecting the difficulties in its ophthalmology division, the company also anticipates an impairment of goodwill of approximately €150 million in the fourth quarter. This non-cash charge indicates a reduction in the estimated future value of the business unit.

Read next

More on Stocks
Back to latest news

LATEST